197 related articles for article (PubMed ID: 34794079)
1. A TNFR2 antibody by countering immunosuppression cooperates with HMGN1 and R848 immune stimulants to inhibit murine colon cancer.
Jiang M; Liu J; Yang D; Tross D; Li P; Chen F; Alam MM; Faustman DL; Oppenheim JJ; Chen X
Int Immunopharmacol; 2021 Dec; 101(Pt A):108345. PubMed ID: 34794079
[TBL] [Abstract][Full Text] [Related]
2. Anti-TNFR2 enhanced the antitumor activity of a new HMGN1/3M-052 stimulated dendritic cell vaccine in a mouse model of colon cancer.
Zhu L; Zhang X; Chen X; Yang D; Nie Y; Pan R; Li L; Wang C; Gui H; Chen S; Jing Q; Wang M; Nie Y
Biochem Biophys Res Commun; 2023 Apr; 653():106-114. PubMed ID: 36868074
[TBL] [Abstract][Full Text] [Related]
3. TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4
He T; Chen Y; Yang D; Islam MS; Chou CK; Liu J; Faustman DL; Oppenheim JJ; Chen X
Cell Oncol (Dordr); 2023 Feb; 46(1):167-177. PubMed ID: 36369606
[TBL] [Abstract][Full Text] [Related]
4. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
[TBL] [Abstract][Full Text] [Related]
5. Antibody-mediated targeting of TNFR2 activates CD8
Tam EM; Fulton RB; Sampson JF; Muda M; Camblin A; Richards J; Koshkaryev A; Tang J; Kurella V; Jiao Y; Xu L; Zhang K; Kohli N; Luus L; Hutto E; Kumar S; Lulo J; Paragas V; Wong C; Suchy J; Grabow S; Dugast AS; Zhang H; Depis F; Feau S; Jakubowski A; Qiao W; Craig G; Razlog M; Qiu J; Zhou Y; Marks JD; Croft M; Drummond DC; Raue A
Sci Transl Med; 2019 Oct; 11(512):. PubMed ID: 31578241
[TBL] [Abstract][Full Text] [Related]
6. MiR-125b-5p modulates the function of regulatory T cells in tumor microenvironment by targeting TNFR2.
Jiang M; Yang Y; Niu L; Li P; Chen Y; Liao P; Wang Y; Zheng J; Chen F; He H; Li H; Chen X
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319063
[TBL] [Abstract][Full Text] [Related]
7. Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer.
Nie Y; He J; Shirota H; Trivett AL; Yang D; Klinman DM; Oppenheim JJ; Chen X
Sci Signal; 2018 Jan; 11(511):. PubMed ID: 29295954
[TBL] [Abstract][Full Text] [Related]
8. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells.
Chen X; Subleski JJ; Kopf H; Howard OM; Männel DN; Oppenheim JJ
J Immunol; 2008 May; 180(10):6467-71. PubMed ID: 18453563
[TBL] [Abstract][Full Text] [Related]
9. Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity.
Chen Y; Jia M; Wang S; Xu S; He N
Front Immunol; 2022; 13():835690. PubMed ID: 35251028
[TBL] [Abstract][Full Text] [Related]
10. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
[TBL] [Abstract][Full Text] [Related]
11. The effects of TNF-α/TNFR2 in regulatory T cells on the microenvironment and progression of gastric cancer.
Qu Y; Wang X; Bai S; Niu L; Zhao G; Yao Y; Li B; Li H
Int J Cancer; 2022 Apr; 150(8):1373-1391. PubMed ID: 34766338
[TBL] [Abstract][Full Text] [Related]
12. Expression of costimulatory TNFR2 induces resistance of CD4+FoxP3- conventional T cells to suppression by CD4+FoxP3+ regulatory T cells.
Chen X; Hamano R; Subleski JJ; Hurwitz AA; Howard OM; Oppenheim JJ
J Immunol; 2010 Jul; 185(1):174-82. PubMed ID: 20525892
[TBL] [Abstract][Full Text] [Related]
13. TNFR2 is critical for the stabilization of the CD4+Foxp3+ regulatory T. cell phenotype in the inflammatory environment.
Chen X; Wu X; Zhou Q; Howard OM; Netea MG; Oppenheim JJ
J Immunol; 2013 Feb; 190(3):1076-84. PubMed ID: 23277487
[TBL] [Abstract][Full Text] [Related]
14. TNFR2-expressing CD4
He J; Li R; Chen Y; Hu Y; Chen X
Prog Mol Biol Transl Sci; 2019; 164():101-117. PubMed ID: 31383403
[TBL] [Abstract][Full Text] [Related]
15. In vitro generated Th17 cells support the expansion and phenotypic stability of CD4(+)Foxp3(+) regulatory T cells in vivo.
Zhou Q; Hu Y; Howard OM; Oppenheim JJ; Chen X
Cytokine; 2014 Jan; 65(1):56-64. PubMed ID: 24080164
[TBL] [Abstract][Full Text] [Related]
16. HMGN1 and R848 Synergistically Activate Dendritic Cells Using Multiple Signaling Pathways.
Alam MM; Yang D; Trivett A; Meyer TJ; Oppenheim JJ
Front Immunol; 2018; 9():2982. PubMed ID: 30619338
[TBL] [Abstract][Full Text] [Related]
17. Regulatory T cells express Tumor Necrosis Factor Receptor 2 with the highest intensity among CD4
Ghods A; Mehdipour F; Shariat M; Talei AR; Ghaderi A
Mol Immunol; 2021 Sep; 137():52-56. PubMed ID: 34214829
[TBL] [Abstract][Full Text] [Related]
18. Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer.
Villarreal DO; L'Huillier A; Armington S; Mottershead C; Filippova EV; Coder BD; Petit RG; Princiotta MF
Cancer Res; 2018 Sep; 78(18):5340-5348. PubMed ID: 30026324
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment with HMGN1 and anti-CD4 depleting antibody reverses T cell exhaustion and exerts robust anti-tumor effects in mice.
Chen CY; Ueha S; Ishiwata Y; Yokochi S; Yang D; Oppenheim JJ; Ogiwara H; Shichino S; Deshimaru S; Shand FHW; Shibayama S; Matsushima K
J Immunother Cancer; 2019 Jan; 7(1):21. PubMed ID: 30696484
[TBL] [Abstract][Full Text] [Related]
20. Scutellarin enhances anti-tumor immune responses by reducing TNFR2-expressing CD4
Chen S; Li R; Chen Y; Chou CK; Zhang Z; Yang Y; Liao P; Wang Q; Chen X
Biomed Pharmacother; 2022 Jul; 151():113187. PubMed ID: 35676787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
